Review

. 2024 Feb;25(2):191-205.

doi: 10.1007/s11864-024-01181-9. Epub 2024 Jan 25.

Impact of PSMA PET on Prostate Cancer Management

Adam B Weiner^{1

2}, Raag Agrawal^{3

4

5}, Luca F Valle^{6

7}, Ida Sonni^{8

9}, Amar U Kishan⁶, Matthew B Rettig^{10

11}, Steven S Raman⁸, Jeremie Calais¹², Paul C Boutros^{10

3

4

5}, Robert E Reiter^{10

5}

Affiliations

¹ Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA. abweiner@mednet.ucla.edu.
² Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA. abweiner@mednet.ucla.edu.
³ Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA.
⁴ Department of Human Genetics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
⁵ Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, USA.
⁶ Department of Radiation Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
⁷ Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
⁸ Department of Radiological Sciences, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
⁹ Department of Clinical and Experimental Medicine, University Magna Graecia, Catanzaro, Italy.
¹⁰ Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
¹¹ Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
¹² Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.

PMID: 38270802
PMCID: PMC11034977
DOI: 10.1007/s11864-024-01181-9

Review

Impact of PSMA PET on Prostate Cancer Management

Adam B Weiner et al. Curr Treat Options Oncol. 2024 Feb.

. 2024 Feb;25(2):191-205.

doi: 10.1007/s11864-024-01181-9. Epub 2024 Jan 25.

Authors

Affiliations

¹ Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA. abweiner@mednet.ucla.edu.
² Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA. abweiner@mednet.ucla.edu.
³ Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA.
⁴ Department of Human Genetics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
⁵ Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, USA.
⁶ Department of Radiation Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
⁷ Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
⁸ Department of Radiological Sciences, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
⁹ Department of Clinical and Experimental Medicine, University Magna Graecia, Catanzaro, Italy.
¹⁰ Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
¹¹ Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
¹² Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.

PMID: 38270802
PMCID: PMC11034977
DOI: 10.1007/s11864-024-01181-9

Abstract

PSMA-PET has been a practice-changing imaging biomarker for the management of men with PCa. Research suggests improved accuracy over conventional imaging and other PET radiotracers in many contexts. With multiple approved PSMA-targeting radiotracers, PSMA PET will become even more available in clinical practice. Its increased use requires an understanding of the prospective data available and caution when extrapolating from prior trial data that utilized other imaging modalities. Future trials leveraging PSMA PET for treatment optimization and management decision-making will ultimately drive its clinical utility.

Keywords: Clinical decision-making; Drug therapy; Neoplasm staging; Positron-emission tomography; Prognosis; Prostatic neoplasms; Radiotherapy; Surgery; Theranostic nanomedicine.

PubMed Disclaimer

Conflict of interest statement

LFV receives salary and research support from the Bristol Myers Squibb foundation for work indirectly related to this manuscript.

PCB sits on the Scientific Advisory Boards of Sage Bionetworks, Intersect Diagnostics Inc. and BioSymetrics Inc.

Cited by

Hematological toxicity of [²²⁵Ac]Ac-PSMA-617 and [¹⁷⁷Lu]Lu-PSMA-617 in RM1-PGLS syngeneic mouse model.
Vilangattil MM, Swaidan A, Godinez J, Taddio MF, Czernin J, Mona CE, Carlucci G. Vilangattil MM, et al. EJNMMI Radiopharm Chem. 2025 Mar 24;10(1):12. doi: 10.1186/s41181-025-00333-y. EJNMMI Radiopharm Chem. 2025. PMID: 40126733 Free PMC article.
Therapeutic Consequences of ⁶⁸Ga-PSMA-11-PET/CT in Prostate Cancer in Correlation to the Gleason Score, PSA Value, and D'Amico-Defined Risk Groups.
Friederike E, Ali E, Spiegel FT, Yousefi BH, Shamim B, Wadim B, Qi W, Andreas P, Laura M, Markus L, Pietro DF, Damiano L. Friederike E, et al. Cancers (Basel). 2025 Jun 11;17(12):1944. doi: 10.3390/cancers17121944. Cancers (Basel). 2025. PMID: 40563594 Free PMC article.
Editorial: PET/CT and MRI in prostate cancer.
Grizzi F, Taverna G. Grizzi F, et al. Front Oncol. 2024 May 24;14:1421542. doi: 10.3389/fonc.2024.1421542. eCollection 2024. Front Oncol. 2024. PMID: 38854714 Free PMC article. No abstract available.
Management Based on Pretreatment PSMA PET of Patients with Localized High-Risk Prostate Cancer Part 2: Prediction of Recurrence-A Systematic Review and Meta-Analysis.
Hoffmann MA, Soydal C, Virgolini I, Tuncel M, Kairemo K, Kapp DS, von Eyben FE. Hoffmann MA, et al. Cancers (Basel). 2025 Feb 28;17(5):841. doi: 10.3390/cancers17050841. Cancers (Basel). 2025. PMID: 40075689 Free PMC article. Review.
Geographic variability in contemporary utilization of PET imaging for prostate cancer: a medicare claims cohort study.
Korn SM, Qian Z, Zurl H, Hansen N, Pohl KK, Stelzl D, Dagnino F, Lipsitz S, Zhang J, Kibel AS, Moore CM, Kilbridge KL, Shariat SF, Loeb S, Vargas HA, Trinh QD, Cole AP. Korn SM, et al. Cancer Imaging. 2025 Jul 4;25(1):86. doi: 10.1186/s40644-025-00898-6. Cancer Imaging. 2025. PMID: 40616108 Free PMC article.

See all "Cited by" articles

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71:209–49. - PubMed
1. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927–35. - PubMed
1. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53:227–30. - PubMed
1. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5. - PubMed
1. Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG. 2-(3-{1-Carboxy-5-[(6[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMAbased PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645–53. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Impact of PSMA PET on Prostate Cancer Management

Affiliations

Impact of PSMA PET on Prostate Cancer Management

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous